SRRK Scholar Rock Inc.: Year-over-year earnings per share growth for the last twelve months

Official company branding of Scholar Rock Holding Corporation (SRRK)

The quarterly earnings per share growth chart allows for an assessment of the business model efficiency of Scholar Rock (SRRK), which is based on US R&D centers and contract manufacturing. By comparing the chart on GURU.Markets, we see how management focuses on clinical data, while the 9.80 metric determines the status of the yield parameter. The team is successfully adapting internal processes for commercialization, leveraging positive late-stage research results.

Scholar Rock Holding Corporation (SRRK) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Scholar Rock

- share price and consensus valuation forecast:
Fundamental company analysis:scholarrock.com, SRRK
Manufactured product of Scholar Rock Inc.

This indicator measures the percentage change in net earnings per share compared to the same quarter of the previous year. Analyzing this trend allows for an assessment of capital management efficiency and business scaling rates. By tracking the quarterly EPS growth rate, an investor can observe the actual speed of change in operating profitability. For Scholar Rock (SRRK), the negative trend reflects the systematic cash burn associated with costly clinical trials. The current earnings deficit is logically driven by the absence of commercial drug sales.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|CNTA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Dyne Therapeutics (DYN)|EWTX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Rapport Pharma RAPP|Alumis Pharma - Year-over-year earnings per share growth for the last twelve months|ZVRA - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Contineum Therapeutics, Inc.|LRMR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata